abcarta
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
abcarta - overview
Established
2018
Location
Suzhou, Jiangsu, China
Primary Industry
Healthcare
About
Founded in 2018 and based in Suzhou, China, abcarta operates as a medical company that focuses on the research and development of intelligent pathology solutions. It was recognized as the National High-tech Enterprise. The company has R&D and production centers, as well as medical information and artificial intelligence centers in Suzhou and San Diego, the United States. In November 2019, abcarta closed a series A funding from new investors Juncheng Capital, Tahoe VC, and Xinyuyan Biotechnology Service (Suzhou).
The company mainly provides intelligent pathology solutions for pathologists, scientific research institutions, and new drug development partners. Products include PathAb antibodies, 100-channel kits, FAIP-30 automatic immunohistochemistry staining instrument, remote pathology diagnosis platform, etc. The company generates revenue by providing intelligent pathology products and services.
Current Investors
Bohe Angel Fund, Tahoe VC, Xinyuyan Biotechnology Service (Suzhou)
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment
Website
www.abcarta.com
Verticals
Artificial Intelligence, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.